KNBIF (Kane Biotech) Debt-to-Equity: -1.35 (As of Mar. 2026)


What is Kane Biotech Debt-to-Equity?

Kane Biotech KNBIF -2.48% Debt-to-Equity is -1.35 as of Mar. 2026. The stock has 6 warning signs investors should review. Among 966 Biotechnology companies, Kane Biotech ranks worse than 103519.57% on this metric.

Kane Biotech's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2026 was $0.93 Mil. Kane Biotech's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2026 was $0.47 Mil. Kane Biotech's Total Stockholders Equity for the quarter that ended in Mar. 2026 was $-1.03 Mil. Kane Biotech's debt to equity for the quarter that ended in Mar. 2026 was -1.35.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Kane Biotech's Debt-to-Equity or its related term are showing as below:

KNBIF' s Debt-to-Equity Range Over the Past 10 Years
Min: -11.09   Med: -1.03   Max: 11.11
Current: -1.35

During the past 13 years, the highest Debt-to-Equity Ratio of Kane Biotech was 11.11. The lowest was -11.09. And the median was -1.03.

KNBIF's Debt-to-Equity is not ranked
in the Biotechnology industry.
Industry Median: 0.16 vs KNBIF: -1.35

Kane Biotech  (OTCPK:KNBIF) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Kane Biotech Debt-to-Equity Related Terms

Kane Biotech Debt-to-Equity Historical Data

* Premium members only.

The historical data trend for Kane Biotech's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kane Biotech Debt-to-Equity Chart

Kane Biotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Debt-to-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.21 -1.05 -0.88 -1.34 -3.08

Kane Biotech Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.83 -11.09 -2.90 -3.08 -1.35

KNBIF vs VRTX, REGN, ALNY: Debt-to-Equity Comparison

For the Biotechnology subindustry, Kane Biotech's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Kane Biotech Debt-to-Equity vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kane Biotech's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Kane Biotech's Debt-to-Equity falls into.


Kane Biotech Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Kane Biotech's Debt to Equity Ratio for the fiscal year that ended in Dec. 2025 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0.961 + 0.71) / -0.542
=-3.08

Kane Biotech's Debt to Equity Ratio for the quarter that ended in Mar. 2026 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0.932 + 0.466) / -1.034
=-1.35

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Debt-to-Equity →
What does a Debt-to-Equity of -1.35 mean?
Kane Biotech (KNBIF) has a Debt-to-Equity of -1.35 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Kane Biotech and its competitors. According to the industry distribution chart, Kane Biotech ranks #999999 out of 966 companies in the Biotechnology industry.
Is Kane Biotech's Debt-to-Equity too high?
Kane Biotech's current Debt-to-Equity is -1.35. Based on the distribution chart, Kane Biotech ranks #999999 out of 966 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Kane Biotech's Debt-to-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Kane Biotech ranks #999999 out of 966 companies for Debt-to-Equity. This places Kane Biotech in the lower half of its industry. The industry median Debt-to-Equity is 0.16. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 966 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Kane Biotech and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kane Biotech's current Debt-to-Equity is -1.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kane Biotech stock overvalued right now?
Kane Biotech (KNBIF) has a current Debt-to-Equity of -1.35. The current Debt-to-Equity is -1.35. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Kane Biotech (KNBIF), the current Debt-to-Equity is -1.35 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Kane Biotech Business Description

Other Exchanges KNE:Canada
Address 290-100 Innovation Drive, Winnipeg, MB, CAN, R3T 6G2
Kane Biotech Inc is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. The company has a portfolio of biotechnologies, intellectual property and products developed by its own biofilm research expertise and acquired from research institutions. The company's operating segments are animal health and human health. It derives maximum revenue from Animal health segment.